Imperva (IMPV) Downgraded to Hold at BidaskClub

Imperva (NASDAQ:IMPV) was downgraded by equities research analysts at BidaskClub from a “buy” rating to a “hold” rating in a research note issued to investors on Tuesday.

Other research analysts have also recently issued research reports about the company. Stifel Nicolaus cut their target price on Imperva from $50.00 to $48.00 and set a “buy” rating on the stock in a research report on Friday, July 27th. Evercore ISI reaffirmed a “buy” rating and set a $56.00 target price on shares of Imperva in a research report on Friday, July 27th. Royal Bank of Canada reaffirmed a “buy” rating and set a $62.00 target price on shares of Imperva in a research report on Friday, July 27th. Zacks Investment Research raised Imperva from a “sell” rating to a “hold” rating in a research report on Tuesday, August 14th. Finally, Oppenheimer cut Imperva from an “outperform” rating to a “market perform” rating and set a $70.00 target price on the stock. in a research report on Friday, July 27th. Two investment analysts have rated the stock with a sell rating, eleven have assigned a hold rating and six have assigned a buy rating to the company. The company currently has an average rating of “Hold” and a consensus target price of $54.00.

Shares of Imperva stock opened at $43.00 on Tuesday. Imperva has a 52 week low of $37.17 and a 52 week high of $57.65. The company has a market capitalization of $1.61 billion, a price-to-earnings ratio of -153.57 and a beta of 1.72.

Imperva (NASDAQ:IMPV) last announced its earnings results on Thursday, July 26th. The software maker reported ($0.26) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.33) by $0.07. The company had revenue of $84.80 million for the quarter, compared to analysts’ expectations of $87.22 million. Imperva had a negative return on equity of 6.92% and a negative net margin of 8.59%. Imperva’s quarterly revenue was up 13.9% on a year-over-year basis. During the same quarter in the previous year, the firm earned $0.24 earnings per share. Equities research analysts expect that Imperva will post -1.15 EPS for the current fiscal year.

A number of hedge funds have recently bought and sold shares of IMPV. Anchor Capital Advisors LLC bought a new stake in shares of Imperva in the second quarter valued at $1,544,000. Legal & General Group Plc raised its stake in shares of Imperva by 27.9% in the second quarter. Legal & General Group Plc now owns 519,725 shares of the software maker’s stock valued at $25,077,000 after buying an additional 113,280 shares during the period. Granahan Investment Management Inc. MA raised its stake in shares of Imperva by 5.7% in the second quarter. Granahan Investment Management Inc. MA now owns 44,961 shares of the software maker’s stock valued at $2,169,000 after buying an additional 2,425 shares during the period. Thompson Siegel & Walmsley LLC bought a new stake in shares of Imperva in the second quarter valued at $11,917,000. Finally, Guggenheim Capital LLC raised its stake in shares of Imperva by 27.4% in the first quarter. Guggenheim Capital LLC now owns 30,865 shares of the software maker’s stock valued at $1,337,000 after buying an additional 6,640 shares during the period. 99.99% of the stock is currently owned by institutional investors and hedge funds.

About Imperva

Imperva, Inc engages in the development, market, sale, and support of cyber security solutions that protect business critical data and applications in the cloud or on premises worldwide. The company's SecureSphere product line provides database, file, and Web application security in various data centers, including on-premises data centers, as well as in private, public, and hybrid cloud computing environments.

Further Reading: What is intrinsic value?

Analyst Recommendations for Imperva (NASDAQ:IMPV)

Receive News & Ratings for Imperva Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Imperva and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply